New Alzheimer’s Drugs (October 2024)

On July 2, 2024, the US Food and Drug Administration (FDA) approved donanemab-azbt, known by the brand name Kisunla, as a treatment for early-stage Alzheimer’s disease. This was exciting news for Alzheimer’s patients and a significant victory for researchers, given…

Addressing Dementia in the Media

Media includes all outlets used as a means of mass communication, including print forms, digital technology, and broadcast media. Media can inform, entertain and communicate topics to a larger audience, which is advantageous when sharing news and other new discoveries…